A METHOD FOR SALIFICATION IN THE TECHNOLOGY OF PREPARING THE INJECTABLE FORMULATIONS OF POORLY SOLUBLE ANTITUMOR COMPOUNDS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. To design a drug is a complex multistep process that begins with studies of the physicochemical properties of an active pharmaceutical ingredient and with selection on an optimal formulation on the basis of the information obtained. Many biologically active substances, including antitumor agents, are poorly soluble in water and highly toxic. These compounds include the folic acid antagonist methotrexate that is widely used in the therapy of cancer and the new alkyl nitrosourea derivative ormustine. Salification is one of the most acceptable ways to overcome low solubility. Objective: to design injectable formulations of antitumor drugs, by converting the active ingredient into the salt formulation, in case of the Russian substance ormustine and a generic version of methotrexate. Material and methods. The investigation objects were methotrexate substance ser. EP 120813 (Hu Zhou Zhanwan Pharmaceutical Co., Ltd., China); ormustine substance (I.Ya. Postovsky Institute of Organic Synthesis, Ural Branch, Russian Academy of Sciences, Russia). Various chemicals, solvents, and reagents, which met the requirements of regulatory documents (GOST, TU, Russian and foreign pharmacopoeias) were used in the investigation. Results. Taking into account the physicochemical properties of antitumor substances, the investigators designed a parenteral ormustine formulation and reproduced a technology for obtaining methotrexate solutions. Water-soluble compounds were prepared through salification: by adding sodium hydroxide for methotrexate and by dissolving in 0.1 M hydrochloric acid for ormustine. Conclusion. Considering the properties of active pharmaceutical ingredients, the authors proposed a new original Ormustin lyophilisate formulation to prepare an injectable solution 125 mg and generic methotrexate injectable solutions 10 and 100 mg/ml.

Full Text

Restricted Access

About the authors

Olga L. Orlova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: orlovaol@mail.ru
leading researcher of the Laboratory for the Development of Dosage Forms of the Research Institute for Experimental Diagnostics and Therapy of Tumors 24, Kashirskoe Shosse, Moscow 115478, Russian Federation

Ludmila L. Nikolaeva

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: alima91@yandex.ru
junior researcher of the Laboratory for the Development of Dosage Forms of the Research Institute for Experimental Diagnostics and Therapy of Tumors; Assistant of the Department of Pharmaceutical Technology and Pharmacology of the Institute of Pharmacy 24, Kashirskoe Shosse, Moscow 115478, Russian Federation; 8, Trubetskaya St., Build. 2, Moscow 119048, Russian Federation

Maria V. Dmitrieva

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: mary.24@mail.ru
researcher of the Laboratory for the Development of Dosage Forms of the Research Institute for Experimental Diagnostics and Therapy of Tumors 24, Kashirskoe Shosse, Moscow 115478, Russian Federation

Anna V. Lantsova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: lantsova1979@mail.ru
senior researcher of the Laboratory for the Development of Dosage Forms of the Research Institute for Experimental Diagnostics and Therapy of Tumors 24, Kashirskoe Shosse, Moscow 115478, Russian Federation

Alevtina P. Polozkova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: elevana@list.ru
researcher of the Laboratory for the Development of Dosage Forms of the Research Institute for Experimental Diagnostics and Therapy of Tumors 24, Kashirskoe Shosse, Moscow 115478, Russian Federation

Zoya S. Shprakh

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: z.shpprakh@ronc.ru
leading researcher of the Laboratory of Chemical-Pharmaceutical Analysis of the Research Institute for Experimental Diagnostics and Therapy of Tumors; Associate Professor of the Department of Pharmaceutical Technology and Pharmacology of the Institute of Pharmacy 24, Kashirskoe Shosse, Moscow 115478, Russian Federation; 8, Trubetskaya St., Build. 2, Moscow 119048, Russian Federation

Natalia Yu. Kulbachevskaya

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: natkulba@mail.ru
head of the Laboratory of Pharmacology and Toxicology f the Research Institute for Experimental Diagnostics and Therapy of Tumors 24, Kashirskoe Shosse, Moscow 115478, Russian Federation

Olga I. Konyaeva

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: olga@bk.ru
senior researcher of the Laboratory of Pharmacology and Toxicology f the Research Institute for Experimental Diagnostics and Therapy of Tumors 24, Kashirskoe Shosse, Moscow 115478, Russian Federation

Natalia A. Oborotova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Email: oborotova@mail.ru
leading researcher of the Laboratory for the Development of Dosage Forms of the Research Institute for Experimental Diagnostics and Therapy of Tumors 24, Kashirskoe Shosse, Moscow 115478, Russian Federation

References

  1. Ланцова А.В., Санарова Е.В., Оборотова Н.А. Противоопухолевые препараты, производные нитрозоалкилмочевины, применяемые для лечения новообразований различного генеза. Биофармацевтический журнал, 2014; 6 (5): 38-51.
  2. Оборотова Н.А., Лопатин П.В. 30 лет лаборатории разработки лекарственных форм РОНЦ им. Н.Н. Блохина РАМН. Российский биотерапевтический журнал, 2004; 3 (4): 3-7.
  3. Барышников А.Ю., Шпрах З.С. Отечественные противоопухолевые препараты. В кн.: Рациональная фармакотерапия в онкологии: руководство для практикующих врачей. Под ред. М.И. Давыдова, В.А. Горбуновой. М.: Изд-во Литтерра, 2015: 95-101.
  4. Барышникова М.А., Альбассит Б., Сапрыкина Н.С., Левит Г.Л., Матвеева Т.В., Краснов В.П. Противоопухолевая активность нового соединения из класса нитрозоалкилмочевин. Российский биотерапевтический журнал, 2013; 12 (1): 8.
  5. IMS Institute, Innovation in cancer care and implications for health systems. Global oncology trend report, 2014.
  6. Соколов А.В. Оригинальные препараты и дженерики: качество, возможные пути решения проблемы. Медицинские технологии. Оценка и выбор, 2012; (3): 52-6.
  7. Ишмухаметов А. Генерическая экспансия на фармрынке ЕС. Ремедиум, 2011; 1: 8-13.
  8. Соколов А.В., Липатова В.С. Оригинальные препараты и дженерики: проблема выбора. Рецепт, 2011; 3: 28-35.
  9. Кузнецова Е.И., Горбачевская Н.Л., Байкова В.Н., Иванов А.В. Связи ЭЭГ и биохимических показателей у детей с лимфобластными опухолями. Нейрохимия, 2005; 22 (2): 131-138.
  10. Иванов А.В., Родионова Г.М., Байкова В.Н., Арзамасцев А.П. Сравнительная оценка методов количественного определения концентрации метотрексата в биологической жидкости и лекарственных формах. Вопросы биологической, медицинской и фармацевтической химии, 2004; (3): 49-52.
  11. Фармацевтическая разработка: концепция и практические рекомендации. Научно-практическое руководство для фармацевтической отрасли. Под ред. С.Н. Быковского С.Н., И.А. Василенко, Н.Б. Деминой, И.Е. Шохина, О.В. Новожилова, А.П. Мешковского, О.Р. Спицкого. М.: Издво Перо, 2015: 472.
  12. Nishiyama M., Eguchi H. Recent advances in cancer chemotherapy: current strategies, pharmacokinetics and pharmacogenomics. Adv. Drug. Deliv. Rev., 2009; 61 (5:) 367-8. https:// doi.org/10.1016/j.addr.2008.11.001
  13. Душкин А.В., Сунцова Л.П., Халиков С.С. Механохимическая технология для повышения растворимости лекарственных веществ. Фундаментальные исследования, 2013; (1): 448-57.
  14. Williams H.D., Trevaskis N.L., Charman S.A., Shanker R.M., Charman W.A., Pouton C.W., Porter C.J.H. Strategies to address low drug solubility in discovery and development. Pharmacological reviews, 2013; 65 (1): 315-499. https://doi. org/10.1124/pr.112.005660
  15. Gulyakin I.D., Oborotova N.A., Pechennikov V.M. Solubilization of Hydrophobic Antitumor Drugs (Review). Pharm. Chem. J., 2014; 48(3): 209-13. https://doi.org/10.1007/s11094014-1078-7
  16. Makary P. Principles of salt formation. UK. J. Pharm & Biosci, 2014; 2 (4): 1-4.
  17. Большаков О.П., Незнанов Н.Г., Бабаханян Р.В. Дидактические и этические аспекты проведения исследований на биомоделях и лабораторных животных. Качественная клиническая практика, 2002; 1: 58-61.
  18. Могилюк В. Аспекты лиофилизационной сушки водных растворов. Фармацевтическая отрасль, 2014; 5 (46): 46-53.
  19. Чалей В.А., Коняева О.И., Ермакова Н.П., Николина А.А., Бухман В.М., Кульбачевская Н.Ю. Доклиническое изучение токсичности нового противоопухолевого препарата ормустин на мелких лабораторных животных. Российский биотерапевтический журнал, 2015; 14 (4): 65-72.
  20. Сапрыкина Н.С., Борисова Л.М., Киселева М.П., Смирнова З.С., Краснов В.П., Левит Г.Л., Мусияк В.В., Барышникова М.А., Бухман В.М., Шпрах З.С., Давыдов М.М. Противоопухолевая активность ормустина на перевиваемых лейкозах мышей. Российский биотерапевтический журнал, 2016; 15 (2): 24-31.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies